Clinical trials: Epithelial Mesothelioma
Malignant Pleural Mesothelioma (MPM)
A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
A phase Ib study investigating the safety, the immunogenicity and the optimal administration frequency of the S-588210 5-peptide vaccine in MPM patients without progression after pemetrexed-based chemotherapy will be conducted.
- Trial name
- NCT02661659
- Testing
- Multipeptide vaccine S-588210
- Where
- United States
- Sponsor
- University of Chicago
Malignant Pleural Mesothelioma, Advanced, Malignant Pleural Mesothelioma, Unresectable
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
This is a national, single arm, phase II trial in patients with diagnosis of unresectable or advanced malignant pleural mesothelioma who experienced progression after platinum-based chemotherapy.
- Trial name
- NCT03786419
- Testing
- Atezolizumab
- Where
- Mexico
- Sponsor
- Health Pharma Professional Research
Malignant Pleural Effusion, Malignant Mesothelioma
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma.
- Conditions
- Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
- Trial name
- (RIOT 4A) (NCT07192900)
- Testing
- locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- David Bartlett, MD
Solid Tumor, Adult, Mesothelioma
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or…
- Conditions
- Solid Tumor, Adult, Mesothelioma, NSCLC
- Trial name
- NCT04665206
- Testing
- VT3989, Nivolumab & Ipilimumab, Osimertinib
- Where
- 12 sites in United States, Australia
- Volunteers
- 434 people
- Sponsor
- Vivace Therapeutics, Inc
Peritoneal Malignant Mesothelioma
Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma
Malignant peritoneal mesothelioma is a rare neoplasm. The most common type, the epithelioid type, has been further divided into histological patterns of tubulo-papillary, acinar, adenomatoid, micropapillary, or solid.
- Trial name
- NCT05193006
- Testing
- No intervention
- Where
- 6 sites in Belgium, France and 4 more
- Volunteers
- 300 people
- Sponsor
- Hospices Civils de Lyon
Mesothelioma, Peritoneal Mesothelioma
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
For cancers, such as mesothelioma, that spread to the lining of the stomach, detecting the cancer is very difficult with CT or MRI scans.
- Trial name
- NCT03867578
- Testing
- HR-MRI, Standard CT Imaging, Ultrasound
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Chicago
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Malignant Pleural Mesothelioma (MPM), Choroidal Nevus
Clinical and Histopathologic Characteristics of BAP1 Mutations
The goal of this protocol is to determine the prevalence of somatic and germline mutations in BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus, primary uveal melanoma (UM), or metastatic UM seen…
- Conditions
- Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM), Metastatic Uveal Melanoma (UM)
- Trial name
- NCT01773655
- Testing
- tumor specimens
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Pleural Effusion, Malignant Mesothelioma
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma.
- Conditions
- Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
- Trial name
- RIOT 4B (NCT07443020)
- Testing
- locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Malignant Pleural Mesotheliomas
Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)
The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .
- Trial name
- VITMPM (NCT02603315)
- Testing
- marker CD74 and vascular endothelial growth factor VEGF
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Lung Cancer, Non-small Cell, Small Cell Lung Cancer
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.
- Conditions
- Lung Cancer, Non-small Cell, Small Cell Lung Cancer, Pleural Mesothelioma
- Trial name
- NCT05628376
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- University College, London
Pleural Mesothelioma, Peritoneal Mesothelioma
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
This phase 2, open-label, single arm study aims to evaluate the efficacy of tremelimumab in combination with the anti-PD-L1 MEDI4736 in patients with unresectable malignant mesothelioma subjects
- Trial name
- NCT02588131
- Testing
- tremelimumab plus MEDI4736
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Italian Network for Tumor Biotherapy Foundation
Mesothelioma
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
Our hypothesis is that the addition of bevacizumab to the standard chemotherapy treatment of MPM will improve overall survival and quality of life beyond that achieved with chemotherapy alone.
- Trial name
- MAPS (NCT00651456)
- Testing
- Standard Chemotherapy (Pemetrexed and Cisplatin), Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
- Where
- 81 sites in France
- Volunteers
- 448 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Malignant Mesothelioma
Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00030745
- Testing
- cisplatin, gemcitabine hydrochloride, conventional surgery
- Where
- Switzerland
- Volunteers
- 61 people
- Sponsor
- Swiss Cancer Institute
Mesothelioma
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
The objective of this study is to determine whether MEDI4736 or combination therapy with MEDI4736 + tremelimumab are associated with favorable alterations of the intratumoral immunologic environment in subjects undergoing…
- Trial name
- NCT02592551
- Testing
- MEDI4736, Tremelimumab, no other name
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Malignant Mesothelioma
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of bortezomib and how well it works in treating patients…
- Trial name
- NCT00513877
- Testing
- bortezomib, quality-of-life assessment
- Where
- 13 sites in Belgium, Ireland and 2 more
- Volunteers
- 33 people
- Sponsor
- Cancer Trials Ireland
Malignant Mesothelioma
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated…
- Trial name
- NCT00509041
- Testing
- dasatinib
- Where
- 37 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in patients with histologically proven advanced malignant pleural mesothelioma (MPM), advanced peritoneal mesothelioma (in dose escalation cohort…
- Conditions
- Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma
- Trial name
- TRAP (NCT02029690)
- Testing
- ADI-PEG 20
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 85 people
- Sponsor
- Polaris Group
Solid Tumors, Triple-Negative Breast Cancer
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT02071862
- Testing
- CB-839, Pac-CB, CBE
- Where
- 13 sites in United States
- Volunteers
- 210 people
- Sponsor
- Calithera Biosciences, Inc